Physician profile
James C Salemis
NPI 1366569329
$23,714.02
in general payments reported to CMS, 2019-2025
44 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,833 · 2020: $1,953 · 2021: $3,506 · 2022: $3,170 · 2023: $3,488 · 2024: $3,557 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,234 · Travel and Lodging: $17.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,233.72 |
| Travel and Lodging | $17.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,656.10 | 2019-2025 | Linzess, Rinvoq, Creon |
| Astrazeneca Pharmaceuticals LP | $3,734.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,700.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $1,569.77 | 2019-2025 | Camzyos, Sotyktu, Eliquis |
| Amgen INC. | $1,294.39 | 2019-2023 | Prolia |
| Janssen Pharmaceuticals, INC | $1,290.62 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,085.44 | 2019-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $966.98 | 2019-2023 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $777.90 | 2022-2025 | |
| Celgene Corporation | $712.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $598.72 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $557.94 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $425.43 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $387.05 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $386.85 | 2024-2025 | Zoryve |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Salemis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.